Vimarsana
Biggest News Aggregation in the World

Page 2 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Statement Today - Breaking & Trending Today

Zoomcar Plans to Add 20000 Additional Cars by 2025 - Vimarsana News

Zoomcar Plans to Add 20000 Additional Cars by 2025

Zoomcar Holdings Inc. Zoomcar or the Company Nasdaq ZCAR the NASDAQlisted leading marketplace for selfdrive car sharing has pumped up their efforts to help local car Hosts add more cars to grow their micro businesses on Zoomcar.

Clear Blue Technologies International to Report 2023 Annual Financial Results and Host Conference Call on Wednesday, May 29, 2024 - Vimarsana News

Clear Blue Technologies International to Report 2023 Annual Financial Results and Host Conference Call on Wednesday, May 29, 2024

Company provides update on Issuance of Management Cease Trade Order by the BCSCTORONTO, May 16, 2024 -- Clear Blue Technologies International Inc. , the Smart Off-Grid™ Company, today announced...

Clear Blue Technologies Announces Issuance of Management Cease Trade Order by the BCSC - Vimarsana News

Clear Blue Technologies Announces Issuance of Management Cease Trade Order by the BCSC

2023 Acquisition of eSite Power Systems requires short extension for successful completion of the audit

Tantalus Releases Results of its Second Annual Utility of the Future Survey - Vimarsana News

Tantalus Releases Results of its Second Annual Utility of the Future Survey

Tantalus Systems , a technology company dedicated to helping utilities modernize their distribution grids by harnessing the power of data, is pleased to announce the findings of its second annual...

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Vimarsana News

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication ...